Skip to main content
. 2012 Sep;87(9):825–834. doi: 10.1016/j.mayocp.2012.05.014

FIGURE 2.

FIGURE 2

Bloodstream infection (BSI) rates in the study population per 1000 treatment days for all BSIs (A) and by year per 1000 treatment days for all prostanoids (B). Numbers in parentheses represent number of BSIs. Data for 2010 extend to the end of the third quarter. Epo = epoprostenol; IV = intravenous; Trep = treprostinil; + = positive; − = negative.